Vascular calcifications:: Pathogenesis, management, and impact on clinical outcomes

被引:121
作者
Cannata-Andia, Jorge B. [1 ]
Rodriguez-Garcia, Minerva [1 ]
Carrillo-Lopez, Natalia [1 ]
Naves-Diaz, Manuel [1 ]
Diaz-Lopez, Bernardino [1 ]
机构
[1] Univ Oviedo, Bone & Mineral Res Unit, Hosp Univ Cent Asturias, Inst Reina Sofia Invest, E-33006 Oviedo, Spain
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 17卷
关键词
D O I
10.1681/ASN.2006080925
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The predisposition to vascular calcifications in patients with chronic kidney disease (CKD) has gained great interest in recent years as many studies have described its likely impact on morbidity and mortality. The mechanism by which the process of vascular calcification is produced is complex, and it does not consist in a simple precipitation of calcium and phosphate but is instead an active and modifiable process. Several "modifiable and nonmodifiable" factors that are able to promote vascular calcification are extremely frequent in patients with CKD. Most of the present strategies to decrease vascular calcifications are based in the control of the more prevalent modifiable risk factors. Unfortunately, the extremely important nortmodifiable risk factors, which are highly prevalent, such as older age, time on dialysis, and diabetes, are not under one's control. Recent studies also have shown that vascular calcifications in some localizations were associated with increased osteoporotic fractures not only in dialysis patients but also in the general population, and interestingly, mortality also was associated significantly and positively with vascular calcifications and nontraumatic bone fractures. Despite that new strategies may improve the management of vascular diseases and specifically have a positive impact on the high prevalence of vascular calcifications, still the best possible control of the bone metabolic and inflammatory parameters are in the primary line. The horizon of the coming decade looks promising, but solid clinical and epidemiologic data are needed to manage better the bone- and cardiovascular-related disorders in patients with CKD.
引用
收藏
页码:S267 / S273
页数:7
相关论文
共 43 条
[31]  
Naves M, 2005, J AM SOC NEPHROL, V16, p728A
[32]   Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis [J].
Nitta, K ;
Akiba, T ;
Suzuki, K ;
Uchida, K ;
Watanabe, RI ;
Majima, K ;
Aoki, T ;
Nihei, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (04) :680-688
[33]   Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption [J].
Price, PA ;
Faus, SA ;
Williamson, MK .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (05) :817-824
[34]   Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism [J].
Ribeiro, S ;
Ramos, A ;
Brandao, A ;
Rebelo, JR ;
Guerra, A ;
Resina, C ;
Vila-Lobos, A ;
Carvalho, F ;
Remedio, F ;
Ribeiro, F .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (08) :2037-2040
[35]  
RODRIGUEZGARCIA M, 2004, J AM SOC NEPHROL, V15, pA175
[36]   Coronary artery calcification in patients with CRF not undergoing dialysis [J].
Russo, D ;
Palmiero, G ;
De Blasio, AP ;
Balletta, MM ;
Andreucci, VE .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (06) :1024-1030
[37]  
Schäfer C, 2003, J CLIN INVEST, V112, P357, DOI [10.1172/JCI200317202, 10.1172/JCI17202]
[38]  
Shanahan CM, 2005, CLIN NEPHROL, V63, P146
[39]   Activated injectable vitamin D and hemodialysis survival:: A historical cohort study [J].
Teng, M ;
Wolf, M ;
Ofsthun, MN ;
Lazarus, JM ;
Hernán, MA ;
Camargo, CA ;
Thadhani, R .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (04) :1115-1125
[40]   Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy [J].
Teng, M ;
Wolf, M ;
Lowrie, E ;
Ofsthun, N ;
Lazarus, JM ;
Thadhani, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05) :446-456